NDAINJECTIONINJECTABLE
Approved
Oct 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Mechanism of Action
arteries. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism.
Indications (1)
Clinical Trials (4)
Users Study Of The Caverject Delivery System
Started Mar 2013
48 enrolled
Healthy
Caverject User Study
Started Feb 2011
48 enrolled
Erectile Dysfunction
Alprostadil in Maculopathy Study (AIMS)
Started Jul 2006
37 enrolled
Macular Degeneration
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Started Mar 2004
840 enrolled
Peripheral Arterial Occlusive Disease